Women's Health · LP-105
Methyldopa Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-105Women's Health
- Generic identity
- MethyldopaTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-105
- Generic ingredient
- Methyldopa
- Dosage form
- Tablet
- Proposed strength
- 250 mg
- Proposed pack
- Blister 10 x 10 tablets
- Portfolio category
- Women's Health
About Methyldopa
Methyldopa is an antihypertensive medicine that acts through the central nervous system to reduce blood pressure. It belongs to a different pharmacological group from diuretics, calcium-channel blockers and renin-angiotensin system medicines. Selection depends on the patient and treatment setting. A tablet catalogue entry does not establish that methyldopa is appropriate for a particular blood-pressure reading or that it should replace an existing prescription.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Long-term blood-pressure management requires reliable measurements, assessment of overall cardiovascular risk and follow-up of response and tolerability. Methyldopa is considered in particular clinical circumstances, including pregnancy-related hypertension under relevant guidance, but no pregnancy-specific protocol is supplied here. Uncontrolled blood pressure or symptoms suggesting acute organ injury need clinical evaluation. External monographs provide ingredient education rather than confirming an authorized Luang Pharma indication.
Important safety considerations
Drowsiness, dizziness and postural symptoms may occur. More serious concerns include liver injury and blood-cell abnormalities, including haemolytic anaemia. Fever, jaundice, unusual weakness or pallor should be assessed promptly. Liver disease, previous methyldopa-related liver reactions and interacting medicines require review. Iron supplements may affect absorption, and sedatives can worsen impairment. Appropriate clinical and laboratory monitoring should be determined by the treating professional.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The entry describes oral tablets. The active-ingredient strength does not establish tablet scoring or suitability for crushing. An authorized label is needed to confirm excipients, handling, contraindications and the exact tablet presentation used in clinical practice.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review blood-pressure measurements, liver history, blood-count monitoring needs, concomitant antihypertensives and interactions. Pregnancy-related treatment decisions require the relevant obstetric and local prescribing guidance.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Methyldopa
- Dosage form / presentation
- Tablet
- Catalogue strength
- 250 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Portfolio category
- Women's Health
Layer 02
Unresolved product-specific fields
- Exact release/coating/scoring characteristics and formulation-specific administration instructions require controlled product documentation where applicable.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Methyldopa — ingredient/formulation referencegovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-105, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-105.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.